Evaxion Biotech A/S (EVAX) Revenue History
Annual and quarterly revenue from 2018 to present
EVAX Revenue Over Time (2018–2025)
EVAX Revenue Growth History
2 of 2 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- +4480.8%
- FY2025 revenue growth
- +125.1%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $0 | -100.0% |
| Q3 2025 | $7.5M | +148.3% |
| Q2 2025 | $37K | -76.0% |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $122K | +67.1% |
| Q3 2024 | $3.0M | — |
| Q2 2024 | $154K | — |
| Q1 2024 | $51K | — |
Multi-year avg. share of annual revenue by fiscal quarter
EVAX Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 22, 2026, Evaxion Biotech A/S (EVAX) generated trailing twelve-month (TTM) revenue of $7.5 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
EVAX's historical revenue data shows various trends over time. Evaxion Biotech A/S's highest annual revenue of $7.5 million was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including NEON (-22.9% YoY), NKTR (-36.2% YoY), and IOVA (+34.3% YoY) — EVAX has underperformed the peer group in revenue growth. Compare EVAX vs NEON →
EVAX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EVAXCurrent | $8M | -100.0% | - | -122.7% | |
 NEON | $2M | -22.9% | -19.2% | -391.5% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 GILD | $29.4B | +3.5% | +3.6% | 39.7% |
EVAX Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.5M | +125.1% | $7.5M | 100.0% | $-9,234,000 | -122.7% |
| 2024 | $3.3M | +4480.8% | $3.3M | 100.0% | $-14,732,000 | -440.6% |
| 2023 | $73K | - | $73K | 100.0% | $-22,197,000 | -30406.8% |
| 2022 | $0 | - | $0 | - | $-25,264,000 | - |
| 2021 | $0 | - | $0 | - | $-25,834,000 | - |
| 2020 | $0 | - | $0 | - | $-16,568,000 | - |
| 2019 | $0 | - | $-80,984 | - | $-11,360,761 | - |
| 2018 | $0 | - | $-73,928 | - | $-5,627,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EVAX — Frequently Asked Questions
Quick answers to the most common questions about buying EVAX stock.
Is EVAX's revenue growth accelerating or slowing?
EVAX revenue is declining -100.0% year-over-year. TTM revenue fell to $8M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is EVAX's revenue history from 2018 to 2026?
Evaxion Biotech A/S (EVAX) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $8M, growing at -100.0% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is EVAX's long-term revenue growth rate (CAGR)?
Evaxion Biotech A/S's 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for EVAX.
Why does EVAX's quarterly revenue fluctuate?
EVAX quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Evaxion Biotech A/S's revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is EVAX's revenue distributed by segment?
EVAX reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does EVAX's revenue compare to industry peers?
Evaxion Biotech A/S (EVAX) with TTM revenue of $8M and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.